The report highlights the company's commitment to sustainability and its focus on promoting ""TE-A-TE"" culture worldwide. Key achievements include the launch of a new mask product made from the stretchy nonwoven fabric used in the company's patch medicines, the re-launch of ""La Salonpas"" with reduced packaging size, and the signing of a license agreement for a novel sodium channel blocker. The report also details the company's Seventh Medium-term Management Policy, HX2025, which sets out ambitious goals for growth and profitability, including expanding its overseas presence and increasing its overseas sales ratio to 50% by FY2025. The company has also made progress on its sustainability initiatives, including reducing CO2 emissions by 28.5% compared to FY2013 and endorsing the TCFD recommendations.
Go back to company
Hisamitsu Pharmaceutical Co Inc 2022 Integrated Report
Issuing Company Hisamitsu Pharmaceutical Co. Inc.
Report Type Integrated Report
Report Language EN
Report Filesize 3.76 MB
No. of Pages 31 pages
Reporting periodMarch 1, 2021-February 28, 2022
Report EditionUnknown
Assurance Provider Unknown
Reporting Standards GRI; SASB; UNSDGs
Materiality Assessmenttrue